UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 524

Sortiert nach

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

The lancet oncology, 2018-05, Vol.19 (5), p.649-659

2018

Volltextzugriff (PDF)

The Steap proteins are metalloreductases

Blood, 2006-08, Vol.108 (4), p.1388-1394

2006

Volltextzugriff (PDF)

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

Cancer cell, 2012-03, Vol.21 (3), p.388-401

2012

Volltextzugriff (PDF)

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B‑Cell Lymphoma

Journal of medicinal chemistry, 2024-07, Vol.67 (13), p.10548-10566

2024

Volltextzugriff (PDF)

Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader

Drug metabolism and pharmacokinetics, 2024-04, Vol.55, p.100957, Article 100957

2024

Volltextzugriff (PDF)

Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells

Nature genetics, 2005-11, Vol.37 (11), p.1264-1269

2005

Volltextzugriff (PDF)

The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron–sulfur cluster biogenesis

Human molecular genetics, 2006-03, Vol.15 (6), p.953-964

2006

Volltextzugriff (PDF)

P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT‐253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS

HemaSphere, 2023-08, Vol.7 (S3), p.e9022892-n/a

2023

Volltextzugriff (PDF)

The Binocular Advantage in Visuomotor Tasks Involving Tools

i-Perception (London), 2013-01, Vol.4 (2), p.101-110

2013

Volltextzugriff (PDF)

Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers

Journal of investigative dermatology, 2024-07

2024

Volltextzugriff (PDF)

Resource allocation in transboundary tuna fisheries: A global analysis

Ambio, 2021-01, Vol.50 (1), p.242-259

2021

Volltextzugriff (PDF)

α3β1 integrin regulates epithelial cytoskeletal organization

Journal of cell science, 1999-09, Vol.112 (17), p.2925-2935

1999

Volltextzugriff (PDF)

Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3170-TPS3170

2022

Volltextzugriff (PDF)

Methane emissions from trees planted on a closed landfill site

Waste management & research, 2022-11, Vol.40 (11), p.1618-1628

2022

Volltextzugriff (PDF)

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.12143-12144

2022

Volltextzugriff (PDF)

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition

Blood, 2022-11, Vol.140 (Supplement 1), p.8862-8864

2022

Volltextzugriff (PDF)

A Mammal-Specific Exon of WT1 Is Not Required for Development or Fertility

Molecular and Cellular Biology, 2002-06, Vol.22 (12), p.4433-4438

2002

Volltextzugriff (PDF)

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Nature medicine, 2023-12, Vol.29 (12), p.3127-3136

2023

Volltextzugriff (PDF)

Abstract LB118: Mechanisms underlying synergistic activity in MYD88MTDLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrate

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB118-LB118

2021

Volltextzugriff (PDF)

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.6239-6240

2022

Volltextzugriff (PDF)

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases

Journal of medicinal chemistry, 2024-08

2024

Volltextzugriff (PDF)

Modelling conservation in the Amazon basin

Nature, 2006-03, Vol.440 (7083), p.520-523

2006

Volltextzugriff (PDF)

Cardiovascular Telemedicine Program in Rural Australia

The New England journal of medicine, 2020-08, Vol.383 (9), p.883-884

2020

Volltextzugriff (PDF)

Selective IRAK4 degradation, not kinase inhibition, blocks TLR-activated NF-Kb and p38 Signaling leading to broad cytokine inhibition

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.111-111.13

2022

Volltextzugriff (PDF)

1 – 25 von 524

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(484)
Mit Volltextzugriff
(472)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

The Steap proteins are metalloreductases

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B‑Cell Lymphoma

Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader

Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells

The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron–sulfur cluster biogenesis

P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT‐253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS

The Binocular Advantage in Visuomotor Tasks Involving Tools

Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers

Resource allocation in transboundary tuna fisheries: A global analysis

α3β1 integrin regulates epithelial cytoskeletal organization

Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Methane emissions from trees planted on a closed landfill site

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition

A Mammal-Specific Exon of WT1 Is Not Required for Development or Fertility

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Abstract LB118: Mechanisms underlying synergistic activity in MYD88MTDLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrate

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases

Modelling conservation in the Amazon basin

Cardiovascular Telemedicine Program in Rural Australia

Selective IRAK4 degradation, not kinase inhibition, blocks TLR-activated NF-Kb and p38 Signaling leading to broad cytokine inhibition

Suchergebnisse filtern